Advertisement

Socioeconomic Issues and Improved Quality of Care

  • John L. GoreEmail author
Chapter

Abstract

The common risk factors for bladder cancer predispose incident cases to men and women with fewer socioeconomic resources than patients with other common cancers. Despite its prevalence—bladder cancer is the fourth most common cancer in US men—advocacy for bladder cancer is nascent and bladder cancer remains underfunded nationally relative to other common cancers. Yet bladder cancer, per capita, is the costliest cancer to treat in the US. Given that the US health care system exhibits marked variations in the delivery and quality of health care services provided, bladder cancer should be a target for broad quality improvement efforts. Nationally, payers are implementing payment changes that will incentivize high value care where high quality care is delivered at lower cost. Herein, we discuss health care disparities in bladder cancer care, the quality of bladder cancer care delivered nationally, and opportunities for quality improvement to optimize the health outcomes of bladder cancer survivors.

Keywords

Bladder cancer Quality of care Health care disparities Comparative effectiveness research Quality of life Quality improvement Radical cystectomy Chemotherapy 

Abbreviations

NMIBC

Non-muscle-invasive bladder cancer

TURBT

Transurethral resection of bladder tumor

SEER

Surveillance Epidemiology, and End Results

NCCN

National Comprehensive Cancer Network

MMC

Mitomycin C

BCG

Bacillus Calmette-Guérin

USQC

Urological Surgery Quality Collaborative

SCOAP

Surgical Care and Outcomes Assessment Program

PQRS

Physicians Quality Reporting System

CMS

Centers for Medicare & Medicaid Services

References

  1. 1.
    Anderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep. 2004;119(3):263–70.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Megwalu II, Vlahiotis A, Radwan M, Piccirillo JF, Kibel AS. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol. 2008;53(3):581–9.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Gore JL, Litwin MS, Lai J, Yano EM, Madison R, Setodji C, et al. Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst. 2010;102(11):802–11.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Wood DP. Urothelial tumors of the bladder. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 10th ed. Philadelphia: Saunders; 2012. p. 2309–34.CrossRefGoogle Scholar
  5. 5.
    Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ. Prevention of bladder cancer: a review. Eur Urol. 2006;49(2):226–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Goy J, Rosenberg MW, King WD. Health risk behaviors: examining social inequalities in bladder and colorectal cancers. Ann Epidemiol. 2008;18(2):156–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54(2):78–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Schoenberg MP, Gonzalgo ML. Management of invasive and metastatic bladder cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 9th ed. Philadelphia: Saunders; 2006. p. 2468–78.Google Scholar
  9. 9.
    Andersen R, Rice TH, Kominski GF. Changing the U.S. health care system: key issues in health services policy and management. 3rd ed. San Francisco: Jossey-Bass; 2007.Google Scholar
  10. 10.
    Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjes JA, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. 2000;55(6):876–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Brookfield KF, Cheung MC, Gomez C, Yang R, Nieder AM, Lee DJ, et al. Survival disparities among African American women with invasive bladder cancer in Florida. Cancer. 2009;115(18):4196–209.PubMedCrossRefGoogle Scholar
  12. 12.
    Johnson EK, Daignault S, Zhang Y, Lee CT. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008;72(3):498–502.PubMedCrossRefGoogle Scholar
  13. 13.
    Lee CT, Dunn RL, Williams C, Underwood 3rd W. Racial disparity in bladder cancer: trends in tumor presentation at diagnosis. J Urol. 2006;176(3):927–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115(1):68–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Mallin K, David KA, Carroll PR, Milowsky MI, Nanus DM. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol. 2011;185(5):1631–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol. 2003;170(5):1765–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011;185(1):72–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Jacobs BL, Montgomery JS, Zhang Y, Skolarus TA, Weizer AZ, Hollenbeck BK. Disparities in bladder cancer. Urol Oncol. 2012;30(1):81–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Taub DA, Hollenbeck BK, Cooper KL, Dunn RL, Miller DC, Taylor JM, et al. Racial disparities in resource utilization for cystectomy. Urology. 2006;67(2):288–93.PubMedCrossRefGoogle Scholar
  20. 20.
    Todd SR, Sommers BD. Overview of the uninsured in the United States: a summary of the 2012 Current Population Survey Report. Washington, DC: U.S. Department of Health and Human Services; 2012. Available from: http://aspe.hhs.gov/health/reports/2012/UninsuredInTheUS/ib.shtml. Accessed 4 Dec 2012.
  21. 21.
    Emanuel EJ. Healthcare, guaranteed: a simple, secure solution for America. 1st ed. New York: PublicAffairs; 2008.Google Scholar
  22. 22.
    Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9(3):222–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Ward EM, Fedewa SA, Cokkinides V, Virgo K. The association of insurance and stage at diagnosis among patients aged 55 to 74 years in the national cancer database. Cancer J. 2010;16(6):614–21.PubMedCrossRefGoogle Scholar
  24. 24.
    Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58(1):9–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Koroukian SM, Bakaki PM, Raghavan D. Survival disparities by Medicaid status: an analysis of 8 cancers. Cancer. 2012;118(17):4271–9.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Vagero D, Persson G. Cancer survival and social class in Sweden. J Epidemiol Community Health. 1987;41(3):204–9.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    The Dartmouth atlas of health care, 1999. Chicago IL: American Hospital Publishing; 1999.Google Scholar
  28. 28.
    McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635–45.PubMedCrossRefGoogle Scholar
  29. 29.
    Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, et al. Bladder cancer. J Natl Compr Canc Netw. 2009;7(1):8–39.PubMedGoogle Scholar
  32. 32.
    David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007;178(2):451–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2011;29(3):252–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Chang SS, Hassan JM, Cookson MS, Wells N, Smith Jr JA. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003;170(4 Pt 1):1085–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol. 2003;169(1):110–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer. 2009;115(5):988–96.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Hollenbeck BK, Taub DA, Dunn RL, Wei JT. Quality of care: partial cystectomy for bladder cancer—a case of inappropriate use? J Urol. 2005;174(3):1050–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Hedgepeth RC, Zhang Y, Skolarus TA, Hollenbeck BK. Variation in use of lymph node dissection during radical cystectomy for bladder cancer. Urology. 2011;77(2):385–90.PubMedCrossRefGoogle Scholar
  39. 39.
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 Pt 1):2186–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011;117(23):5392–401.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009;115(12):2660–70.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003;95(8):588–97.PubMedCrossRefGoogle Scholar
  43. 43.
    Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, et al. Quality of care in patients with bladder cancer: a case report? Cancer. 2012;118(5):1412–21.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Huang GJ, Hamilton AS, Lo M, Stein JP, Penson DF. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol. 2008;180(2):520–4.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Barocas DA, Liu A, Burks FN, Suh RS, Schuster TG, Bradford T, et al. Practice-based collaboration to improve the use of immediate intravesical therapy after resection for non-muscle-invasive bladder cancer. J Urol. 2013;190(6):2011–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Miller DC, Murtagh DS, Suh RS, Knapp PM, Dunn RL, Montie JE. Establishment of a urological surgery quality collaborative. J Urol. 2010;184(6):2485–90.PubMedCrossRefGoogle Scholar
  48. 48.
    Birkmeyer NJ, Share D, Campbell Jr DA, Prager RL, Moscucci M, Birkmeyer JD. Partnering with payers to improve surgical quality: the Michigan plan. Surgery. 2005;138(5):815–20.PubMedCrossRefGoogle Scholar
  49. 49.
    Flum DR, Fisher N, Thompson J, Marcus-Smith M, Florence M, Pellegrini CA. Washington State’s approach to variability in surgical processes/outcomes: Surgical Clinical Outcomes Assessment Program (SCOAP). Surgery. 2005;138(5):821–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Share DA, Campbell DA, Birkmeyer N, Prager RL, Gurm HS, Moscucci M, et al. How a regional collaborative of hospitals and physicians in Michigan cut costs and improved the quality of care. Health Aff (Millwood). 2011;30(4):636–45.CrossRefGoogle Scholar
  51. 51.
    Kwon S, Florence M, Grigas P, Horton M, Horvath K, Johnson M, et al. Creating a learning healthcare system in surgery: Washington State’s Surgical Care and Outcomes Assessment Program (SCOAP) at 5 years. Surgery. 2012;151(2):146–52.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Miller DC, Murtagh DS, Suh RS, Knapp PM, Schuster TG, Dunn RL, et al. Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer. J Urol. 2011;186(3):844–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117–27.PubMedCrossRefGoogle Scholar
  54. 54.
    Hollenbeck BK, Taub DA, Miller DC, Dunn RL, Montie JE, Wei JT. The regionalization of radical cystectomy to specific medical centers. J Urol. 2005;174(4 Pt 1):1385–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128–37.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Hollenbeck BK, Dunn RL, Miller DC, Daignault S, Taub DA, Wei JT. Volume-based referral for cancer surgery: informing the debate. J Clin Oncol. 2007;25(1):91–6.PubMedCrossRefGoogle Scholar
  57. 57.
    The Leapfrog Group Fact Sheet. Washington, DC: The Leapfrog Group; 2012. Available from: http://www.leapfroggroup.org/about_us/leapfrog-factsheet. Accessed 29 Oct 2012
  58. 58.
    Kernisan LP, Lee SJ, Boscardin WJ, Landefeld CS, Dudley RA. Association between hospital-reported Leapfrog Safe Practices Scores and inpatient mortality. JAMA. 2009;301(13):1341–8.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    FACT SHEET: Blue Distinction®. 2012. Available from: http://www.bcbs.com/why-bcbs/blue-distinction/blue-distinction-fact-sheet.pdf. Accessed Oct 15 2012.
  60. 60.
    Physician Quality Reporting System. Baltimore, MD: Centers for Medicare & Medicaid Services; 2012. Available from: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/index.html?redirect=/PQRS. Accessed 22 Oct 2012.
  61. 61.
    PQRS Toolkit. Linthicum, MD: American Urological Association; 2012. Available from: http://www.auanet.org/content/health-policy/regulation-and-reimbursement/payor-information/pqrs-toolkit.cfm. Accessed Jun 2013.
  62. 62.
    Lotan Y, Cadeddu JA, Roehrborn CG, Stage KH. The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. J Urol. 2004;172(5 Pt 1):1958–62.PubMedCrossRefGoogle Scholar
  63. 63.
    Hussey PS, Sorbero ME, Mehrotra A, Liu H, Damberg CL. Episode-based performance measurement and payment: making it a reality. Health Aff (Millwood). 2009;28(5):1406–17.CrossRefGoogle Scholar
  64. 64.
    Hernandez V, De La Pena E, Martin MD, Blazquez C, Diaz FJ, Llorente C. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol. 2011;29(4):409–14.PubMedCrossRefGoogle Scholar
  65. 65.
    Miller DC, Gust C, Dimick JB, Birkmeyer N, Skinner J, Birkmeyer JD. Large variations in Medicare payments for surgery highlight savings potential from bundled payment programs. Health Aff (Millwood). 2011;30(11):2107–15.CrossRefGoogle Scholar
  66. 66.
    Chang SS, Cookson MS, Baumgartner RG, Wells N, Smith Jr JA. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol. 2002;167(5):2012–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Hollenbeck BK, Miller DC, Taub D, Dunn RL, Khuri SF, Henderson WG, et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol. 2005;174(4 Pt 1):1231–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Konety BR, Allareddy V, Herr H. Complications after radical cystectomy: analysis of population-based data. Urology. 2006;68(1):58–64.PubMedCrossRefGoogle Scholar
  69. 69.
    Gilbert SM, Dunn RL, Miller DC, Daignault S, Ye Z, Hollenbeck BK. Mortality after urologic cancer surgery: impact of non-index case volume. Urology. 2008;71(5):906–10.PubMedCrossRefGoogle Scholar
  70. 70.
    Stimson CJ, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE, et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010;184(4):1296–300.PubMedCrossRefGoogle Scholar
  71. 71.
    Overview list—how many smokefree laws? Berkeley, CA: American Nonsmokers’ Rights Foundation; 2013. Available from: http://www.no-smoke.org/pdf/mediaordlist.pdf. Accessed Jun 2013.

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of UrologyUniversity of WashingtonSeattleUSA
  2. 2.Fred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations